This antibody-drug Ozogamicin represents a significant step forward in the treatment of acute leukemic cancer, especially severe myeloid disease (AML). The medication combines a engineered immunoglobulin aimed against the target marker located on abnormal cells with calicheamicin, resulting in specific cell death. Hence, it offers a possibly altern